Last reviewed 2026-04-22 · How we verify

HGP1408

HGP1408 is a selective androgen receptor degrader (SARD) that binds to and degrades the androgen receptor protein, eliminating both its transcriptional activity and protein expression.

HGP1408 is a selective androgen receptor degrader (SARD) that binds to and degrades the androgen receptor protein, eliminating both its transcriptional activity and protein expression. Used for Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer.

At a glance

Mechanism of action

Unlike traditional androgen receptor antagonists that block ligand binding, HGP1408 recruits the androgen receptor to the proteasome for degradation, resulting in complete loss of receptor function. This mechanism may overcome resistance mechanisms seen with conventional anti-androgens and provide more comprehensive suppression of androgen-driven signaling in hormone-sensitive cancers.

Approved indications

• Castration-resistant prostate cancer (CRPC)
• Hormone-sensitive prostate cancer

Common side effects

• Fatigue
• Hot flashes
• Nausea
• Decreased libido

Key clinical trials

• Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis (PHASE3)
• PK and Safety Study of HCP1102, HGP0813 and HGP1408 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• HGP1408 CI brief — competitive landscape report
• HGP1408 updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI